PE20210110A1 - Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso - Google Patents

Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso

Info

Publication number
PE20210110A1
PE20210110A1 PE2020001249A PE2020001249A PE20210110A1 PE 20210110 A1 PE20210110 A1 PE 20210110A1 PE 2020001249 A PE2020001249 A PE 2020001249A PE 2020001249 A PE2020001249 A PE 2020001249A PE 20210110 A1 PE20210110 A1 PE 20210110A1
Authority
PE
Peru
Prior art keywords
bind
binding proteins
nkg2d
methods
specific binding
Prior art date
Application number
PE2020001249A
Other languages
English (en)
Inventor
Gregory P Chang
Ann F Cheung
Asya Grinberg
Dhruv Kam Sethi
William Haney
Bianka Prinz
Bradley M Lunde
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of PE20210110A1 publication Critical patent/PE20210110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen proteinas de union multiespecificas que se unen y matan celulas cancerosas humanas que expresan a CD33 (Siglec-3), asi como composiciones farmaceuticas y metodos terapeuticos utiles para el tratamiento de cancer que expresa CD33. La invencion se refiere a proteinas de union multiespecificas que se unen a celulas cancerosas humanas que expresan CD33 y exhiben alta potencia y lisis maxima de celulas diana en comparacion con anticuerpos monoclonales anti-CD33
PE2020001249A 2018-02-20 2019-02-20 Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso PE20210110A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632756P 2018-02-20 2018-02-20
US201862677137P 2018-05-28 2018-05-28
PCT/US2019/018751 WO2019164930A1 (en) 2018-02-20 2019-02-20 Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use

Publications (1)

Publication Number Publication Date
PE20210110A1 true PE20210110A1 (es) 2021-01-19

Family

ID=67688572

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001249A PE20210110A1 (es) 2018-02-20 2019-02-20 Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso

Country Status (15)

Country Link
US (2) US20210101976A1 (es)
EP (1) EP3755721A4 (es)
JP (2) JP7353576B2 (es)
KR (1) KR20200132875A (es)
CN (1) CN112119093A (es)
AU (1) AU2019225741A1 (es)
BR (1) BR112020016939A2 (es)
CA (1) CA3091424A1 (es)
CL (2) CL2020002144A1 (es)
IL (1) IL276778A (es)
MX (1) MX2020008684A (es)
PE (1) PE20210110A1 (es)
SG (1) SG11202007945UA (es)
TW (1) TW201942134A (es)
WO (1) WO2019164930A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
US20210101976A1 (en) * 2018-02-20 2021-04-08 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508017A (ja) * 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
EP3936521A1 (en) * 2013-03-15 2022-01-12 Xencor, Inc. Heterodimeric proteins
EP3148580B1 (en) * 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
NZ733580A (en) * 2015-01-02 2024-02-23 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
JP7034066B2 (ja) * 2015-10-02 2022-03-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する二重特異性抗体
WO2017081190A1 (en) * 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CA3054079A1 (en) * 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
AU2019218125A1 (en) * 2018-02-08 2020-08-20 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
US20210101976A1 (en) * 2018-02-20 2021-04-08 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
MX2020008683A (es) * 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Dominios variables de anticuerpo que se dirigen a cd33 y sus usos.
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
US20220378831A1 (en) * 2019-09-25 2022-12-01 Fate Therapeutics, Inc. Multi-targeting effector cells and use thereof
CA3177024A1 (en) * 2020-05-06 2021-11-11 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a

Also Published As

Publication number Publication date
EP3755721A4 (en) 2021-12-22
US20220380459A1 (en) 2022-12-01
CN112119093A (zh) 2020-12-22
CA3091424A1 (en) 2019-08-29
TW201942134A (zh) 2019-11-01
JP2023164908A (ja) 2023-11-14
SG11202007945UA (en) 2020-09-29
BR112020016939A2 (pt) 2020-12-15
JP7353576B2 (ja) 2023-10-02
JP2021514396A (ja) 2021-06-10
WO2019164930A1 (en) 2019-08-29
AU2019225741A1 (en) 2020-09-17
EP3755721A1 (en) 2020-12-30
IL276778A (en) 2020-10-29
MX2020008684A (es) 2020-12-07
KR20200132875A (ko) 2020-11-25
CL2020002144A1 (es) 2021-03-26
CL2023002108A1 (es) 2024-02-16
US20210101976A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
PE20210110A1 (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
EA201790060A1 (ru) Биспецифические cd33- и cd3-связывающие белки
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
AR122018A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
EA201792581A1 (ru) Способы применения биспецифических cd33- и cd3- связывающих белков
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
EA202092302A1 (ru) Антитела к trem-1 и их применения
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
EA202192488A1 (ru) Антитела против tsg-6 и их применения
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
AR127896A1 (es) Proteínas que se unen a nkg2d, cd16 y 5t4